immunotherapies – media

Silencing Protein could Enhance Immunotherapy Efficacy in Cancer Tumors

Silencing an earlier known protein could hamper tumor development and increase the efficacy of immunotherapy treatments, researchers discovered at the Bloomberg~Kimmel Institute for Cancer Immunotherapy in the Johns Hopkins Kimmel Cancer Center.
- Source: MedicalXpress
- 744
- August 2, 2018
cancer immunotherapies Researches
Harvard’s Wyss Institute partners with Cellectis to recode the human genome

Recode project will use Cellectis’ TALEN gene editing technology to create first virus-resistant human cells for manufacturing therapeutics and developing new cell-based therapies
- Source: immunotherapies
- 648
- May 4, 2018
CAR T-cells Cellectis immunotherapies Market Views
Researchers develop new technology platform for cancer immunotherapy

Johns Hopkins researchers have invented a new class of immunotherapeutic agents that are more effective at harnessing the power of the immune system to fight cancer. Their approach results in significant inhibition of tumor growth, even against cancers which do not respond to existing immunotherapies used in the clinic. In collaboration with Insilico Medicine, a Baltimore-based leader in artificial intelligence for drug discovery, the team reports their results this week in Nature Communications.
- Source: immunotherapies
- 517
- February 27, 2018
cancer immunotherapies Researches
Boosting cancer therapy with cross-dressed immune cells

Researchers at EPFL have created artificial molecules that can help the immune system to recognize and attack cancer tumors. The study is published in Nature Methods. Immunotherapies are breakthrough treatments that stimulate the patient’s immune cells to attack the tumor through the recognition of aberrant molecules called tumor antigens. They can be very effective, but currently can only cure a minority of patients with solid tumors. Researchers and physicians are now looking into ways of increasing the precision and strength of the immune attack on the tumor. Dendritic cell vaccines One approach is the “dendritic cell vaccine”. Dendritic cells are specialized immune cells whose role is to capture antigens from foreign bodies and present them to the immune system’s killer T cells, which will then attack and destroy the invaders. For the vaccine, dendritic cells are taken out of the patient, “force-fed” with tumor antigens, and finally re-injected back into ...
- Source: medicalxpress
- 582
- January 25, 2018
artificial molecules cancer tumor immunotherapies Researches
Bay Area’s Medeor Therapeutics Bags $57M

Medeor Therapeutics announced it had closed on an oversubscribed Series B financing worth $57 million. The round was led by RA Capital Management. New investors included Sofinnova Ventures and 6 Dimensions Capital. They were joined by existing investors Vivo Capital and WuXi Healthcare Ventures.
- Source: Biospace
- 618
- November 28, 2017
cellular immunotherapies Market Views Series
FDA Lifts Clinical Hold on Cellectis Phase 1 Clinical Trials with UCART123 in AML and BPDCN

Cellectis (Alternext: ALCLS - Nasdaq: CLLS) a clinical-stage biopharmaceutical company focused on developing immunotherapies based on gene-edited allogeneic CAR T-cells (UCART), today announced that the U.S. Food and Drug Administration (FDA) has lifted the clinical hold, previously announced on September 4, 2017, on Phase 1 trials of Cellectis’ UCART123 product candidate in acute myeloid leukemia (AML) and blastic plasmacytoid dendritic cell neoplasm (BPDCN).
- Source: Cellectis
- 564
- November 9, 2017
Cellectis Clinical Trials FDA immunotherapies UCART
‘Synthetic gene circuit’ may improve effectiveness of cancer immunotherapy

Synthetic gene circuits that only trigger powerful, tumor-specific immune responses when they detect certain disease markers may help immunotherapies to fight cancer more effectively, according to a new study.
- Source: medicalnewstoday
- 689
- October 20, 2017
cancer immunotherapies Synthetic gene

your submission has already been received.

OK

Subscribe

Please enter a valid Email address！

Submit

The most relevant industry news & insight will be sent to you every two weeks.

more

more

Customer Services
Contact Us
Help Center

Buy on Drugdu.com
Browse Product Categories

Free APP

Follow Us

Terms & Conditions | Privacy Policy

粤ICP备16008861号

Copyright © 2016-2018 Drugdu.com. All Rights Reserved.